PMV Pharmaceuticals (PMVP) Expected to Announce Earnings on Friday

PMV Pharmaceuticals (NASDAQ:PMVP) is expected to be releasing its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect PMV Pharmaceuticals to post earnings of ($0.40) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. On average, analysts expect PMV Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PMV Pharmaceuticals Price Performance

Shares of NASDAQ PMVP opened at $1.37 on Wednesday. PMV Pharmaceuticals has a 1 year low of $0.81 and a 1 year high of $1.88. The stock has a market cap of $73.06 million, a P/E ratio of -0.92 and a beta of 1.41. The firm has a 50-day moving average of $1.42 and a 200 day moving average of $1.31.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PMVP. Shay Capital LLC purchased a new position in PMV Pharmaceuticals in the second quarter worth about $26,000. Squarepoint Ops LLC raised its holdings in PMV Pharmaceuticals by 101.8% in the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after buying an additional 13,367 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after buying an additional 21,334 shares during the last quarter. Algert Global LLC purchased a new position in PMV Pharmaceuticals in the third quarter worth about $87,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in PMV Pharmaceuticals in the third quarter worth about $96,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PMVP. Weiss Ratings raised shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. Evercore raised shares of PMV Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.